Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences on May 14, 2025, "Innovations in Internal Medicine"

internal medicine, Internal Medicine Sciences’ Council of the Russian Academy of Sciences, heart failure, noncommunicable diseases, hypertension, cardiovascular risk, remote monitoring, respiratory diseases, suicide prevention

1. Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol. 2024;21(10):717-34. doi:10.1038/s41569-024-01046-6.

2. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624-34. doi:10.1056/NEJMoa1304127.

3. Artyukov I, Arutyunov G, Bobrov M, et al. The first observation of osmotically neutral sodium accumulation in the myocardial interstitium. Sci Rep. 2021;11(1):22025. doi:10.1038/s41598-021-01443-8.

4. Dragunov DO, Sokolova AV, Arutjunov GP. Development and Va­li­dation of a Questionnaire to Assess the Level of Salt Intake in the Adult Population of the Russian Federation Using Machine Learning Methods. The Russian Archives of Internal Medicine. 2024;14(4):284-97. (In Russ.) doi:10.20514/2226-6704-2024-14-4-284-297.

5. Dragunov DO, Pershina ES, Sokolova AV, et al. Detection of ex­cess sodium in the myocardium under conditions of sodium loading using dual-energy computed tomography. Diagnostic radio­logy and radiotherapy. 2020;11(1):52-8. (In Russ.) doi:10.22328/2079-5343-2020-11-1-52-58.

6. Dragunov DO, Sokolova AV, Arutyunov GP. Pilot Study on the Impact of Excessive Salt Intake on Human Myocardial Mecha­nics. Proceedings of the Research Institute for Healthcare Or­ga­nization and Medical Management: Collection of scientific papers. M.: Research Institute for Healthcare Organization and Medical Management, 2025. p. 214-7. (In Russ.) EDN SBZVCG.

7. Dragunov DO, Sokolova AV, Mitrokhin VM, et al. Impact of salt in­take on inflammation markers in cardiovascular disease: a ret­ro­spective observational case-control study. Kuban Scientific Medical Bulletin. 2021;28(5):47-63. (In Russ.) doi:10.25207/1608-6228-2021-28-5-47-63.

8. Dragunov DO, Sokolova AV, Mitrokhin VM, et al. The impact of high-salt diet and diuretics on the development of the aestival phenomenon in patients with chronic heart failure. Front Nutr. 2025;12:1538962. doi:10.3389/fnut.2025.1538962.

9. Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21. (In Russ.)

10. Arutyunov GP, Kafarskaya LI, Savelov NA, et al. Chronic heart fai­lure: structural and microbiological changes in the co­lon. Te­ra­pev­ticheskii arkhiv. 2007;79(2):31-7. (In Russ.)

11. Arutyunov GP, Kafarskaya LI, Vlasenko VK. Intestinal microflora in patients with chronic heart failure as a possible factor in the occurrence and generalization of systemic inflammation. Serdechnaya nedostatochnost'. 2003;4(5):256-60. (In Russ.)

12. Sokolova AV, Dragunov DO, Klimova AV, et al. Prognostic Sig­ni­ficance of Plasma Short-­Chain Fatty Acid Levels in Assessing Mor­tality Risk in Patients with Chronic Heart Failure and Sar­co­penia. Int J Mol Sci. 2025;26(13):5984. doi:10.3390/ijms26135984.

13. Sokolova AV, Klimova AV, Dragunov DO, et al. Effect of metformin therapy on muscle mass and strength in patients with and without diabetes. Meta-analysis of 15 studies. Russian Journal of Cardiology. 2021;26(3):4331. (In Russ.) doi:10.15829/1560-4071-2021-4331.

14. Klimova AV, Sokolova AV, Dragunov DO, et al. The Effect of Metformin on Short-­Chain Fatty Acid Levels in Patients with Chronic Heart Failure, Prediabetes, and Sarcopenia. Kardiologiia. 2025;65(4):46-51. (In Russ.) doi:10.18087/cardio.2025.4.n2836.

15. Arutyunov GP, Kostyukevich OI, Bylova NA. Prevalence, clinical sig­nificance of malnutrition and the effectiveness of nutritional sup­port in patients suffering from chronic heart failure. Expe­ri­men­tal and Clinical Gastroenterology. 2009;(2):22-33. (In Russ.)

16. Boulet J, Sridhar VS, Bouabdallaoui N, et al. Inflammation in heart failure: pathophysiology and therapeutic strategies. Inflamm Res. 2024;73(5):709-23. doi:10.1007/s00011-023-01845-6.

17. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016; 2016(1):CD011047. doi:10.1002/14651858.CD011047.pub2.

18. Kobalava ZhD, Tolkacheva VV, Vatsik-­Gorodetskaya MV, et al. Implementation of a "seamless" model of providing specialized medical care to patients with heart failure. RUDN Journal of Medicine. 2023;27(2):141-54. doi:10.22363/2313-0245-2023-27-2-141-154.

19. Galochkin SA, Bagmanova NKh, Kazakhmedov ER, et al. Decom­pensation triggers of various phenotypes of chronic heart failure. Clin Pharmacol Ther = Klinicheskaya farmakologiya i terapiya. 2020;29(3):37-43. (In Russ.) doi:10.32756/0869-5490-2020-3-37-43.

20. Erina AM, Rotar OP, Solntsev VN, et al. Epidemiology of Arterial Hypertension in Russian Federation — Importance of Choice of Criteria of Diagnosis. Kardiologiia. 2019;59(6):5-11. (In Russ.) doi:10.18087/cardio.2019.6.2595.

21. Kobalava ZhD, Stavtseva YuV, Troitskaya EA, et al. Blood pres­su­re phenotypes in young patients with type 1 diabetes. Rus­sian Journal of Cardiology. 2020;25(3):3729. (In Russ.) doi:10.15829/1560-4071-2020-3-3729.

22. Ezhova N, Khomova I, Shavarova E, et al. Early Renal Damage in Young Hypertensive Subjects: Link with Office And 24-Hour Am­bulatory Systolic and Diastolic Blood Pressure. Journal of Hyper­tension. 2021;39:e302. doi:10.1097/01.hjh.0000747948.79546.f4.

23. Shavarova EK, Khomova IA, Kobalava ZhD, et al. High normal blood pressure and left ventricular structural and functional disorders in young adults. Cardiovascular Therapy and Pre­ven­tion. 2022;21(8):3282. (In Russ.) doi:10.15829/1728-8800-2022-3282.

24. Velmakin S, Troitskaya E, Kobalava Zh. Hypertensive Patients with Rheumatoid Arthritis Are Characterized by Higher Levels of The Office Blood Pressure and Worse Control of Central Blood Pressure Compared to The Controls. Journal of Hypertension. 2019;37:e317. doi:10.1097/01.hjh.0000573948.13946.b6.

25. Padaryan S, Shavarova E, Kotovskaya Y, et al. Alternative solution for central hemodynamics parameters assessment with a new tacho-­oscillometric device. European Journal of Heart Failure. 2017;19:284-5.

26. Omboni S, Posokhov I, Parati G, et al. Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry. J Clin Hypertens (Greenwich). 2019;21(8):1155-68. doi:10.1111/jch.13623.

27. Chernomorets V, Troitskaya E, Kobalava Zh. Hypertensive Patients with Type 2 Diabetes Mellitus and Proteinuric Phenotype of Chronic Kidney Disease Are Characterized by Worse Parameters of 24-H Central Aortic Blood Pressure. Journal of Hypertension. 2021;39.

28. Kobalava ZhD, Tolkacheva VV, Nazarov IS, et al. The effectiveness of the algorithm for diuretic therapy under the control of natriuresis in patients with acute decompensation of heart failure in the intensive care unit: a prospective intervention controlled study. Annals of Critical Care. 2024;(4):139-48. (In Russ.)

29. Kobalava Z, Jordaan P, Kotovskaya Y, et al. Short-term treatment with LCZ696 in patients with stable chronic heart failure: Effect on biomarkers [abstract P5716]. Eur Heart J. 2013;34(suppl 1):1066.

30. Kobalava Z, Pavlikova E, Averkov O, et al. First experience with concomitant AT1 and neprilysin inhibition with LCZ696 in patients with chronic heart failure. Circulation. 2010;122(21 Suppl):19378.

31. Medovchshikov VV, Yeshniyazov NB, Khasanova ER, et al. Newly diagnosed type 2 diabetes and prediabetes in hospitalized patients with cardiovascular diseases: prevalence and conformity of baseline blood pressure, lipids and HbA1c to target levels. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2020;29(4):31-5. (In Russ.) doi:10.32756/0869-5490-2020-4-31-35.

32. Kobalava Z, Tolkacheva V, Khutsishvili N, et al. WATCH-DM score in assessing the risk of adverse clinical outcomes in patients with type 2 diabetes and heart failure with preserved ejection fraction. Klini cheskaya farmakologiya i terapiya = Clin Phar ma col Ther. 2024;33(3):26-30. (In Russ.) doi:10.32756/0869-5490-2024-3-26-30.

33. Gudieva K, Safarova A, Kobalava Zh. Use of the HFA-PEFF al­go­rithm for diagnosis of heart failure with preserved left ven­tri­cular ejection fraction. Clin Pharmacol Ther = Klinicheskaya farma­ko­logiya i terapiya. 2020;29(2):47-50 (In Russ.) doi:10.32756/0869-5490-2020-2-47-50.

34. Abdulloev D, Pavlikov G, Timofeeva T, et al. The impact of ABCDE stress echocardiography results with exercise on the management of patients with diabetes mellitus and coronary artery disease. Abstracts of the Heart Failure 2025, 17-20 May 2025, Belgrade, Serbia. European Journal of Heart Failure. 2025;27 Suppl 2:372. doi:10.1002/ejhf.3736.

35. Safarova AF, Kobalava ZhD, Mamedov SV, et al. Clinical as­sociations of subclinical pulmonary congestion in patients with primary acute myocardial infarction after percutaneous coronary intervention. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2021;30(1):43-50. (In Russ.) doi:10.32756/0869-5490-2021-1-43-50.

36. Kotova EO, Pisaryuk AS, Lokhonina AV, et al. Cytokine profile of surgical patients with infective endocarditis. Rational Pharmacotherapy in Cardiology. 2025;21(1):4-13. (In Russ.) doi:10.20996/1819-6446-2025-3125.

37. Kotova EO, Moiseeva AY, Kobalava ZD, et al. Proinflammatory cytokines IL-6, IL-1β, TNF-α in infective endocarditis. Tera­pev­ticheskii arkhiv. 2024;96(4):342-8. (In Russ.) doi:10.26442/00403660.2024.04.202711.

38. Kotova EO, Kobalava ZhD, Pisaryuk AS, et al. Molecular Biological Methods in The Etiological Diagnostics of Infective Endocarditis. Kardiologiia. 2025;65(3):10-20. (In Russ.) doi:10.18087/cardio.2025.3.n2869.

39. Kobalava Z, Tolkacheva V, Cabello-­Montoya F, et al. Predictive value of the integral assessment of congestion in patients with chronic heart failure. Revista Latinoamericana de Hipertensión. 2022;17(2):105-12.

40. Vatsik-­Gorodetskaya M, Tolkacheva V, Cabello-­Montoya F, et al. Comprehensive assessment of the hydration status in patients with acute decompensated heart failure: clinical associations and prognostic significance. Klini cheskaya farmakologiya i terapiya = Clin Phar macol Ther. 2023;32(1):42-8. (In Russ.) doi:10.32756/0869-5490-2023-1-42-48.

41. Kobalava ZhD, Aslanova RSh, Safarova A F, et al. Bedside ultrasound assessment of venous congestion by VExUS protocol in heart failure: clinical associations and prognostic value. Rational Pharmacotherapy in Cardiology. 2023;19(4):341-9. (In Russ.) doi:10.20996/1819-6446-2023-2921.

42. Soloveva A, Kobalava Z, Fudim M, et al. Relationship of Liver Stiffness with Congestion in Patients Presenting with Acute Decompensated Heart Failure. J Card Fail. 2019;25(3):176-87. doi:10.1016/j.cardfail.2019.01.020.

43. Khutsishvili N, Misan IA, Arisheva OS, et al. Diagnostic and pro­gnostic value of NT-proBNP in patients with non-alco­holic fatty liver disease and acute decompensated heart failure. European Heart Journal. Acute Cardiovascular Care. 2024;13: zuae036.070. doi:10.1093/ehjacc/zuae036.070.

44. Cabello FE, Misan IA, Arisheva OS, et al. The impact of nonalco­holic fatty liver disease on ultrasound parameters of congestion and prognosis in heart failure patients. Eur J Heart Fail. 2023;25: 3-457.

45. Khutsishvili N, Misan IA, Arisheva OS, et al. The structure of liver damage in patients with acute decompensated heart failure, the prognostic role of steatosis and liver density. European Heart Journal. Acute Cardiovascular Care. 2024;13:zuae036.069. doi:10.1093/ehjacc/zuae036.069.

46. Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023;389(14):1273-85. doi:10.1056/NEJMoa2206916.

47. Astrakova (Benimetskaya) KS, Mikheenko IL, Uranov AE, et al. The Impact of Clinical Decision Support Systems on Adherence to Clinical Guidelines and Achieving Target Levels of Low-­Density Lipoprotein Cholesterol in Patients at Risk of Developing Cardiovascular Events (SuccESS). Rational Pharmacotherapy in Cardiology. 2024;20(6):625-36. (In Russ.) doi:10.20996/1819-6446-2024-3138.

48. National suicidology guideline. Edited by Polozhy BS. M.: Medical Information Agency, 2019. p. 600. (In Russ.) ISBN: 978-5-9986-0392-1.

49. Timerbulatov IF, Yevtushenko EM. Experience in upgrading psy­chotherapeutic care in the Republic of Bashkortostan. Rus­sian Journal of Psychiatry. 2015;4:66-8. (In Russ.)

50. Timerbulatova MF, Akhmadeev RR, Mukhamadeev TR, et al. Neuropsychological analysis of problematic digital tech­no­lo­gy use in adolescents. Report 2 — event-­related electro­en­ce­phalography during emotional assessment of IAPS visual stimuli. Bull Neurol Psychiatry Neurosurg. 2025;18(6):717-29. (In Russ.) doi:10.33920/med-01-2506-02.

51. Bakirov LR, AkhmadeevRR, Yuldashev VL, et al. Psychomet­ric Projective Indicators of Students’ Perception of The Inter­net. Bashkortostan Medical Journal. 2015;10(5):90-4.(In Russ.)

52. Kas'yanov ED, Nikilishin AE, Rukavishnikov GV, et al. Clinical features of early-­onset depression: focus on neurovegetative symp­toms. Russ J Psychiatr. 2021;2:43-53. (In Russ.) doi:10.47877/1560-957X-2021-10205.

53. Kazantseva AV, Davydova YD, Enikeeva RF, et al. The association study of polymorphic variants of hypothalamic-­pituitary-adrenal system genes (AVPR1B, OXTR) and aggressive behavior manifestation: a focus on social environment. Research Results in Biomedicine. 2021;7(3):232-44. doi:10.18413/2658-6533-2021-7-3-0-3.

54. Gareeva AE, Borodina LS, Pozdnyakov SA, et al. Pharma­co­ge­nomic and pharmacometabolomic biomarkers of the efficacy and safety of antidepressants: focus on selective serotonin reuptake inhibitors. S. S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):26-35. (In Russ.) doi:10.17116/jnevro202412406126.